FujiFilm VisualSonics has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its Vevo MD ultra high frequency clinical ultrasound system.


The Vevo MD system is designed for image resolution down to 30 micrometers, and is compatible with FujiFilm VisualSonics UHF series of transducers that have ability to operate in a range of frequencies up to 70 Mhz.

The system, which has already secured approval in Europe, can be applied in a range of clinical fields such as neonatology & pediatrics, vascular, musculoskeletal, dermatology and other small parts within the first 3 cm of the body.

FujiFilm VisualSonics vice president & general manager Renaud Maloberti said: "With the Vevo MD, clinicians can observe the tiniest, most highly detailed anatomy that has never been seen before, which means greatly enhanced potential for diagnoses."

FujiFilm VisualSonics is a subsidiary of FujiFilm SonoSite and a part of FujiFilm Holdings.

FujiFilm SonoSite president & CEO Masayuki Higuchi said: "This powerful and innovative technology offers unprecedented image resolution capabilities that will have significant impact on the U.S. medical imaging community and the care providers deliver to patients."

In September 2015, Fujifilm Sonosite secured CE mark approval for its point-of-care solution, iViz, a platform which integrates ultrasound with medical IT.

The platform allows clinical users, ranging from hospital settings to clinics in remote villages, to undertake ultrasound when and where it is required.

Image: The Vevo MD is claimed to be the world’s first ultra high frequency ultrasound for humans. Photo: courtesy of FUJIFILM VisualSonics, Inc.